Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 13 Best American Penny Stocks to Invest In. On February 6, H.C. Wainwright reiterated its Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $9 on the stock.

This update followed the company’s February 5 announcement of data showing a best-in-class profile for its commercial therapy Amtagvi (lifileucel). Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shared that the treatment delivered unprecedented response rates in a real-world clinical, retrospective study of patients with advanced melanoma that cannot be removed by surgery or has spread to other parts of the body.

According to the report by Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), Amtagvi is the first one-time T cell therapy for a solid tumor cancer. It is also the only FDA-approved treatment for advanced melanoma patients who have already been treated with anti-PD-1 and targeted therapy, where applicable. The results were presented in an oral session at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City.

Earlier, on February 4, Barclays also reiterated its Overweight rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $10 on the stock.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial biotechnology company focused on developing tumor-infiltrating lymphocyte (TIL) therapies for patients with cancer.

While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 AI Stocks That Are Skyrocketing and 12 Best Oil and Gas Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.